Programmatic Management of Drug-resistant TB (PMDT): While the causes of multi-drug resistant TB are similar in all high burden countries
(low adherence, weak DOTS, poor treatment compliance, inadequate drug supplies, direct transmission, etc.).
Globally, few children with drug-resistant (DR) tuberculosis (TB) are identiﬁed, diagnosed, and given an appropriate treatment. Although advances have been made in critical high burden countries such as Bangladesh to increase access to quality care and treatment for DR TB, this disease is still considered largely to be a problem for adults, and children who are infected remain too often in the shadows, unable to access care.
Malawi is a low income country with a population of about 15 million. TB remains a major public health problem in the country. According to the WHO World TB Report 2012, there were an estimated 29,000 new cases of TB (all forms) in the year 2011, and approximately 18,000 of these were HIV positive. The HIV pandemic presents a significant challenge to global TB control. The USAID TB CARE II Malawi project, launched in 2010, is a 5 year coordinated effort led by URC in collaboration with Project HOPE and PIH. The project assists the National TB Program in improving TB control and expanding access to high quality TB and TB/HIV services in the public sector. The project recently developed infographics designed to highlight project successes spanning the past 21 months.
While AIDS has taken the lead in terms of disease threat to humankind, tuberculosis (TB) remains a serious threat, especially where it attacks people with HIV/AIDS. This report presents 2003–2004 survey data of private sector TB practices in Cambodia so that decision-makers can move forward in ensuring proper case management of TB and stemming its spread while using precious resources effectively.
This eight module course on multidrug-resistant tuberculosis (MDR-TB) is designed as a self-study online introductory course on MDR-TB for physicians. Each chapter is accompanied with a quiz based on the content of that chapter.
The course presents general principles of MDR-TB control, it doesn't reflect country specific regulations due to variation in policy and guidlines across borders.
Fighting drug resistant TB requires expertise and innovation. TB CARE II is tackling this need by working with TB policy makers and implementers to develop a network of experts and resources to strengthen national and regional drug resistant TB programs. Building from the expertise available through Partners In Health Technical Assistance Centers (TAC) in Lesotho, Russia and Peru (through PIH sister organization Socios En Salud), TB CARE II is working to support the development of TACs so we can share experiences to build effective PMDT worldwide.
Many countries are in the process of establishing or scaling up treatment of drug-resistant tuberculosis (DR TB). Effectively scaling up treatment will require addressing health systems–related issues, such as task shifting to alleviate human resources shortages and greater community engagement. A principal challenge in establishing or scaling up treatment of DR TB is deciding what model of care to implement. A crucial step is bridging the gap between the hospital and the community to ensure continuity of care. For DR TB treatment to be truly patient-centered, patients must be supported in their homes and communities.
This report on TB drug resistance by the World Health Organization (WHO) updates “Anti-tuberculosis drug resistance in the world: Report No. 4” published by WHO in 2008. It summarizes the latest data and provides latest estimates of the global epidemic of multidrug and extensively drug-resistant tuberculosis (M/XDR-TB). For the first time, this report includes an assessment of the progress countries are making to diagnose and treat MDR-TB cases.